We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-12.76%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$277M
AUM Growth
-$51.6M
Cap. Flow
+$14.5M
Cap. Flow %
5.25%
Top 10 Hldgs %
42.56%
Holding
60
New
17
Increased
8
Reduced
13
Closed
11

Top Buys

Rank Stock Value
1
STXS icon
Stereotaxis
STXS
+$15.6M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$12.5M
3
TVRD
Tvardi Therapeutics
TVRD
+$10.2M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$6.8M
5
QTRX icon
Quanterix
QTRX
+$5.16M

Top Sells

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$9.31M
2
CMRX
Chimerix, Inc.
CMRX
+$6.35M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$5.75M
4
ARVN icon
Arvinas
ARVN
+$4.84M
5
TGTX icon
TG Therapeutics
TGTX
+$3.75M

Sector Composition

Rank Sector Weight
1 Healthcare 99.16%
2 Miscellaneous 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDXS icon
1
Codexis
CDXS
$182M
$18.5M 6.7%
1,350,000
– –
STXS icon
2
Stereotaxis
STXS
$147M
$14.3M 5.17%
+4,070,000
New +$15.6M
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$14.1M 5.09%
1,365,000
– –
HROW icon
4
Harrow
HROW
$1.44B
$13.3M 4.82%
2,370,000
+160,000
+7% +$1.05M
EIDX
5
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$11M 3.97%
305,550
– –
TPTX
6
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$10.8M 3.91%
+287,500
New +$12.5M
AMRN
7
Amarin Corp
AMRN
$297M
$9.78M 3.54%
32,250
– –
ODT
8
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$9.11M 3.29%
350,000
-75,000
-18% -$2.51M
OCUL icon
9
Ocular Therapeutix
OCUL
$2.38B
$8.44M 3.05%
2,775,000
-175,000
-6% -$782K
AXGN icon
10
Axogen
AXGN
$2.78B
$8.38M 3.03%
700,000
-200,000
-22% -$3.29M
QURE icon
11
uniQure
QURE
$3.44B
$8.07M 2.92%
205,000
– –
TVRD
12
Tvardi Therapeutics
TVRD
$24M
$8.04M 2.91%
+12,222
New +$10.2M
BOLD
13
DELISTED
Audentes Therapeutics, Inc
BOLD
$8.01M 2.9%
285,000
+5,000
+2% +$171K
DCPH
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$7.81M 2.82%
230,000
-80,000
-26% -$2.37M
BPMC
15
DELISTED
Blueprint Medicines
BPMC
$7.71M 2.79%
105,000
-20,000
-16% -$1.73M
CYTK icon
16
Cytokinetics
CYTK
$10.8B
$7.4M 2.67%
650,000
-250,000
-28% -$3.14M
XOMA
17
DELISTED
Xoma
XOMA
$7.39M 2.67%
375,000
-25,000
-6% -$448K
ETON icon
18
Eton Pharmaceutcials
ETON
$1.79B
$7.36M 2.66%
1,165,000
+90,000
+8% +$574K
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$5.12B
$7.2M 2.6%
200,000
– –
AVTX icon
20
Avalo Therapeutics
AVTX
$1.08B
$7.19M 2.6%
759
– –
BHVN
21
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$6.67M 2.41%
160,000
+10,000
+7% +$422K
PTCT icon
22
PTC Therapeutics
PTCT
$5.99B
$6.43M 2.32%
190,000
-36,388
-16% -$1.58M
TCDA
23
DELISTED
Tricida, Inc. Common Stock
TCDA
$6.02M 2.18%
195,000
– –
ATXI
24
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
$5.68M 2.05%
847
+20
+2% +$136K
KYNB
25
Kyntra Bio
KYNB
$32.4M
$5.55M 2.01%
6,000
– –
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2019 Portfolio in Review

As of Q3 2019, Opaleye Management held 60 positions worth $277M, down 16% from $328M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opaleye Management deployed $14.5M of net new capital in Q3 2019, opening 17 new positions and adding to 8 existing holdings. Its largest new stake was Stereotaxis: 4,070,000 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was TG Therapeutics, an estimated $3.75M trimmed.

  • Opaleye Management's largest Q3 2019 buy was Stereotaxis: 4,070,000 shares worth $14.3M.
  • Opaleye Management added most to Crinetics Pharmaceuticals in Q3 2019, an estimated $3.33M increase.
  • Opaleye Management's biggest Q3 2019 reduction was TG Therapeutics, cutting an estimated $3.75M.
  • Opaleye Management fully exited Lexicon Pharmaceuticals in Q3 2019, selling an estimated $9.31M.
  • Opaleye Management's ten largest holdings make up 43% of its $277M portfolio in Q3 2019.
  • Opaleye Management opened 17 new positions and closed 11 in Q3 2019.
  • Opaleye Management's portfolio value fell 16% quarter-over-quarter to $277M.

Based on Opaleye Management's 13F filing for Q3 2019, filed 14 Nov 2019.